Restenosis after PCI. Part 1: pathophysiology and risk factors

Restenosis is a complex disease for which the pathophysiological mechanisms have not yet been fully elucidated, but are thought to include inflammation, proliferation, and matrix remodeling. Over the years, many predictive clinical, biological, (epi)genetic, lesion-related, and procedural risk factors for restenosis have been identified. These factors are not only useful in risk stratification of patients, they also contribute to our understanding of this condition. Furthermore, these factors provide evidence on which to base treatment tailored to the individual and aid in the development of novel therapeutic modalities. In this Review, we will evaluate the available evidence on the pathophysiological mechanisms of restenosis and provide an overview of the various risk factors, together with the possible clinical application of this knowledge.

[1]  M. Uslenghi,et al.  The World Space Observatory (WSO-UV) - Current status , 2008, 0801.2080.

[2]  W. Siegenthaler,et al.  Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. , 1979, The New England journal of medicine.

[3]  L. Bentivoglio Percutaneous transluminal coronary angioplasty. , 1979, Annals of internal medicine.

[4]  R E Vlietstra,et al.  Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. , 1984, The American journal of cardiology.

[5]  F Joffre,et al.  Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. , 1987, The New England journal of medicine.

[6]  A. Hassid,et al.  Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. , 1989, The Journal of clinical investigation.

[7]  M. Savage,et al.  Restenosis after coronary angioplasty: A multilvariate statistical model to relate lesion and procedure variables to restenosis☆ , 1991 .

[8]  T. Ogihara,et al.  A potent genetic risk factor for restenosis , 1993, Nature Genetics.

[9]  E. Topol,et al.  Quantitative analysis of factors influencing late lumen loss and restenosis after directional coronary atherectomy. , 1993, The American journal of cardiology.

[10]  Charles L. Brown,et al.  Can restenosis after coronary angioplasty be predicted from clinical variables? , 1993, Journal of the American College of Cardiology.

[11]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.

[12]  R. Califf Restenosis: the cost to society. , 1995, American heart journal.

[13]  J. Pollock,et al.  Restenosis is associated with decreased coronary artery nitric oxide synthase. , 1997, International journal of cardiology.

[14]  M. Hadamitzky,et al.  Predictive factors of restenosis after coronary stent placement. , 1997, Journal of the American College of Cardiology.

[15]  P. Amouyel,et al.  D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. , 1997, Circulation.

[16]  D. Holmes,et al.  Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[17]  A. Kastrati,et al.  Interlesion dependence of the risk for restenosis in patients with coronary stent placement in in multiple lesions. , 1998, Circulation.

[18]  M. Leon,et al.  In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. , 1998, Journal of the American College of Cardiology.

[19]  M. Leon,et al.  The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. , 1998, Journal of the American College of Cardiology.

[20]  M. Hadamitzky,et al.  Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. , 1998, Journal of the American College of Cardiology.

[21]  G. Stone,et al.  Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. , 1999, Circulation.

[22]  C. Di Mario,et al.  Stented segment length as an independent predictor of restenosis. , 1999, Journal of the American College of Cardiology.

[23]  A. Kastrati,et al.  PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. , 1999, Circulation.

[24]  J. Pell Does smoking cessation reduce the risk of restenosis following coronary angioplasty? , 2000, Heart.

[25]  Christian W Hamm,et al.  Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis , 2000, The Lancet.

[26]  J. Danesh,et al.  Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses , 2000, BMJ : British Medical Journal.

[27]  M. Lamfers,et al.  Adenoviral Expression of a Urokinase Receptor–Targeted Protease Inhibitor Inhibits Neointima Formation in Murine and Human Blood Vessels , 2001, Circulation.

[28]  J. Popma,et al.  Impact of Smoking on Clinical and Angiographic Restenosis After Percutaneous Coronary Intervention: Another Smoker’s Paradox? , 2001, Circulation.

[29]  M. Lamfers,et al.  In vivo suppression of restenosis in balloon-injured rat carotid artery by adenovirus-mediated gene transfer of the cell surface-directed plasmin inhibitor ATF.BPTI , 2001, Gene Therapy.

[30]  J. Jukema,et al.  Genetic aspects of restenosis after percutaneous coronary interventions: towards more tailored therapy. , 2001, European heart journal.

[31]  D. Baim,et al.  Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. , 2002, Journal of the American College of Cardiology.

[32]  A. Zwinderman,et al.  A meta-analysis of the angiotensin-converting enzyme gene polymorphism and restenosis after percutaneous transluminal coronary revascularization: evidence for publication bias. , 2002, American heart journal.

[33]  R. Erbel,et al.  Evaluation of metal allergies in patients with coronary stents , 2002, Contact dermatitis.

[34]  U. Ikeda,et al.  Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. , 2002, Atherosclerosis.

[35]  Gary S. Mintz,et al.  Intravascular Ultrasound Guidance Improves Angiographic and Clinical Outcome of Stent Implantation for Long Coronary Artery Stenoses: Final Results of a Randomized Comparison With Angiographic Guidance (TULIP Study) , 2003, Circulation.

[36]  D. Sedding,et al.  Mechanosensitive p27Kip1 Regulation and Cell Cycle Entry in Vascular Smooth Muscle Cells , 2003, Circulation.

[37]  Rossella Fattori,et al.  Drug-eluting stents in vascular intervention , 2003, The Lancet.

[38]  A. Kastrati,et al.  Tumor necrosis factor-α, lymphotoxin-α, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting , 2003 .

[39]  A. Kastrati,et al.  Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. , 2003, Cytokine.

[40]  J. Brophy,et al.  Evidence for Use of Coronary Stents: A Hierarchical Bayesian Meta-Analysis , 2003, Annals of Internal Medicine.

[41]  Lawrence Joseph,et al.  Evidence for Use of Coronary Stents , 2003 .

[42]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[43]  Robyn L McClelland,et al.  Clinical and Angiographic Predictors of Restenosis After Percutaneous Coronary Intervention: Insights From the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) Trial , 2004, Circulation.

[44]  B. Zinman,et al.  Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. , 2004, Diabetes care.

[45]  D. Baim,et al.  Beyond Restenosis: Five-Year Clinical Outcomes From Second-Generation Coronary Stent Trials , 2004, Circulation.

[46]  J. Jukema,et al.  Genetic predictive factors in restenosis. , 2004, Pathologie-biologie.

[47]  Michael S. Lee,et al.  Molecular and cellular basis of restenosis after percutaneous coronary intervention: the intertwining roles of platelets, leukocytes, and the coagulation–fibrinolysis system , 2004, The Journal of pathology.

[48]  A. Zwinderman,et al.  Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era. , 2004, European heart journal.

[49]  A. Mangi,et al.  Enhanced Inhibition of Neointimal Hyperplasia by Genetically Engineered Endothelial Progenitor Cells , 2004, Circulation.

[50]  T. Walley,et al.  Angioplasty and stents in coronary artery disease: a systematic review and meta‐analysis , 2004, Scandinavian cardiovascular journal : SCJ.

[51]  I. Iakovou,et al.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.

[52]  V. Fuster,et al.  Looking for the culprit of coronary in‐stent restenosis: debatable role for the fibrinolytic system? , 2005, Journal of thrombosis and haemostasis : JTH.

[53]  Y. Jang,et al.  Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. , 2005, The American journal of cardiology.

[54]  P. Serruys,et al.  Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Coronary Stents: Three-Year Results of the RAVEL Trial , 2005, Circulation.

[55]  S. Anker,et al.  A frequent toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis , 2005, Journal of Molecular Medicine.

[56]  A. Zwinderman,et al.  Tumor necrosis factor- plays an important role in restenosis development , 2005 .

[57]  A. Zwinderman,et al.  Tumor necrosis factor-alpha plays an important role in restenosis development. , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[58]  A. Zwinderman,et al.  Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention. , 2005, Diabetes care.

[59]  K. Huber,et al.  Predictive value of plasma plasminogen activator inhibitor‐1 for coronary restenosis: dependence on stent implantation and antithrombotic medication , 2005, Journal of thrombosis and haemostasis : JTH.

[60]  Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. , 2005, International journal of molecular medicine.

[61]  A. Zwinderman,et al.  Genetic Inflammatory Factors Predict Restenosis After Percutaneous Coronary Interventions , 2005, Circulation.

[62]  A. Kastrati,et al.  Predictive Factors of Restenosis After Coronary Implantation of Sirolimus- or Paclitaxel-Eluting Stents , 2006, Circulation.

[63]  Matthew H Samore,et al.  Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. , 2006, Journal of the American College of Cardiology.

[64]  U. Dietz,et al.  Shortening the stent length reduces restenosis with bare metal stents: matched pair comparison of short stenting and conventional stenting , 2005, Heart.

[65]  岩澤 秀明,et al.  Asymmetric Dimethylarginine , 2006, Definitions.

[66]  B. Binder Thrombin is bad, accepted; but is smoking good to prevent restenosis? , 2006, Journal of thrombosis and haemostasis : JTH.

[67]  A. Zwinderman,et al.  Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1 , 2006, Pharmacogenetics and genomics.

[68]  G. Montalescot,et al.  Drug eluting stents: an updated meta-analysis of randomised controlled trials , 2005, Heart.

[69]  Junbo Ge,et al.  Elevated matrix metalloproteinase expression after stent implantation is associated with restenosis. , 2006, International journal of cardiology.

[70]  P. Quax,et al.  Inhibition of Complement Component C3 Reduces Vein Graft Atherosclerosis in Apolipoprotein E3–Leiden Transgenic Mice , 2006, Circulation.

[71]  A. Zwinderman,et al.  Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention , 2007, Genes and Immunity.

[72]  A. Feinberg,et al.  Genetics and epigenetics--nature's pen-and-pencil set. , 2007, The New England journal of medicine.

[73]  U. Galderisi,et al.  Pathophysiology of stem cells in restenosis. , 2007, Histology and histopathology.

[74]  Plasminogen activator inhibitor-1 and restenosis. , 2007, Current drug targets.

[75]  K. Kent,et al.  Correlates of clinical restenosis following intracoronary implantation of drug-eluting stents. , 2007, The American journal of cardiology.

[76]  T. Murohara,et al.  Genetic risk for restenosis after coronary stenting. , 2007, Atherosclerosis.

[77]  T. Lagerweij,et al.  The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden mice. , 2007, Atherosclerosis.

[78]  Stéphane G Carlier,et al.  Intravascular ultrasound assessment of drug-eluting stent expansion. , 2007, American heart journal.

[79]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[80]  A. Zwinderman,et al.  The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions , 2007, Thrombosis and Haemostasis.

[81]  F. Burzotta,et al.  Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. , 2008, Cardiovascular revascularization medicine : including molecular interventions.

[82]  Frederic S. Resnic,et al.  Long-Term Clinical Outcomes After Drug-Eluting and Bare-Metal Stenting in Massachusetts , 2008, Circulation.

[83]  Timothy O'Brien,et al.  Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[84]  G. Maurer,et al.  Plasminogen activator inhibitor‐1 predicts coronary in‐stent restenosis of drug‐eluting stents , 2008, Journal of thrombosis and haemostasis : JTH.

[85]  A. Zwinderman,et al.  Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions , 2008, Human mutation.

[86]  H. Putter,et al.  Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. , 2008, Journal of the American College of Cardiology.

[87]  J. Jukema,et al.  Epigenetic histone acetylation modifiers in vascular remodelling – new targets for therapy in cardiovascular disease , 2008, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

[88]  N. Weissman,et al.  The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. , 2008, European heart journal.

[89]  F. Schmidt Meta-Analysis , 2008 .

[90]  A. Itai,et al.  The effects of pharmacological PAI-1 inhibition on thrombus formation and neointima formation after arterial injury. , 2008, Expert opinion on therapeutic targets.

[91]  M. Kimura,et al.  Predictors of angiographic restenosis after drug eluting stents in the coronary arteries: contemporary practice in real world patients. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[92]  B. Brott,et al.  Stainless Steel Ions Stimulate Increased Thrombospondin-1-Dependent TGF-Beta Activation by Vascular Smooth Muscle Cells: Implications for In-Stent Restenosis , 2009, Journal of Vascular Research.

[93]  E. Erdoğan,et al.  A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine , 2010, Heart and Vessels.

[94]  A. V. Rij,et al.  Active matrix metalloproteinases 3 and 9 are independently associated with coronary artery in-stent restenosis. , 2009, Atherosclerosis.

[95]  D. Wei,et al.  Important role of TNF-alpha in inhibitory effects of Radix Sophorae Flavescentis extract on vascular restenosis in a rat carotid model of balloon dilatation injury. , 2009, Planta medica.

[96]  P. Kala,et al.  Nuclear receptors gene polymorphisms and risk of restenosis and clinical events following coronary stenting. , 2009, Vnitrni lekarstvi.

[97]  P. Teirstein,et al.  A Randomized Controlled Trial of Angiography Versus Intravascular Ultrasound-Directed Bare-Metal Coronary Stent Placement (The AVID Trial) , 2009, Circulation. Cardiovascular interventions.

[98]  A. Zwinderman,et al.  Metabolic Background Determines the Importance of NOS3 Polymorphisms in Restenosis after Percutaneous Coronary Intervention: A Study in Patients with and without the Metabolic Syndrome , 2006, Disease markers.

[99]  F. Baas,et al.  p27kip1–838C>A Single Nucleotide Polymorphism Is Associated With Restenosis Risk After Coronary Stenting and Modulates p27kip1 Promoter Activity , 2009, Circulation.

[100]  D. Lawrence,et al.  Recombinant Plasminogen Activator Inhibitor-1 Inhibits Intimal Hyperplasia , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[101]  Taro Saito,et al.  Metal allergic reaction in chronic refractory in-stent restenosis. , 2009, Cardiovascular revascularization medicine : including molecular interventions.

[102]  M. Pencina,et al.  Predicting Restenosis of Drug-Eluting Stents Placed in Real-World Clinical Practice: Derivation and Validation of a Risk Model From the EVENT Registry , 2010, Circulation. Cardiovascular interventions.

[103]  M. Amiji,et al.  Non-viral eNOS gene delivery and transfection with stents for the treatment of restenosis , 2010, Biomedical engineering online.

[104]  J. Jukema,et al.  A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease. , 2010, Cardiovascular research.

[105]  P. Serruys,et al.  The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardi , 2010, JACC. Cardiovascular interventions.

[106]  G. Lemesle,et al.  Impact of intravascular ultrasound guidance in patients with acute myocardial infarction undergoing percutaneous coronary intervention , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[107]  A. Uitterlinden,et al.  Vitamin D receptor: a new risk marker for clinical restenosis after percutaneous coronary intervention , 2010, Expert opinion on therapeutic targets.

[108]  V. Pasceri,et al.  Role of endothelial progenitor cells in restenosis and progression of coronary atherosclerosis after percutaneous coronary intervention: a prospective study. , 2010, JACC. Cardiovascular interventions.

[109]  P. Serruys,et al.  Coronary stents: current status. , 2010, Journal of the American College of Cardiology.

[110]  G. Maurer,et al.  Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a. , 2010, Atherosclerosis.

[111]  M. Klomp,et al.  Understanding the role of endothelial progenitor cells in cardiovascular disease, coronary artery lesion progression, and in-stent restenosis. , 2010, JACC. Cardiovascular interventions.

[112]  P. de Knijff,et al.  Matrix Metalloproteinases 2 and 3 Gene Polymorphisms and the Risk of Target Vessel Revascularization after Percutaneous Coronary Intervention: Is There Still Room for Determining Genetic Variation of MMPs for Assessment of an Increased Risk of Restenosis? , 2011, Disease markers.

[113]  Y. Dundar,et al.  Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. , 2015, The Cochrane database of systematic reviews.

[114]  A. Yeung,et al.  Impact of C-reactive protein on in-stent restenosis: a meta-analysis. , 2010, Texas Heart Institute journal.

[115]  Gary S Mintz,et al.  In-stent restenosis in the drug-eluting stent era. , 2010, Journal of the American College of Cardiology.

[116]  E. Edelman,et al.  Revascularization for coronary artery disease in diabetes mellitus: Angioplasty, stents and coronary artery bypass grafting , 2010, Reviews in Endocrine and Metabolic Disorders.

[117]  R. Weiss,et al.  Meta-analysis of incidence, clinical characteristics and implications of stent fracture. , 2010, The American journal of cardiology.

[118]  G. Niccoli,et al.  The evolving role of inflammatory biomarkers in risk assessment after stent implantation. , 2010, Journal of the American College of Cardiology.

[119]  J. Veselka,et al.  CORONARY ARTERY DISEASE Original Studies Long-Term Health Outcome and Mortality Evaluation After Invasive Coronary Treatment Using Drug Eluting Stents with or without the IVUS Guidance. Randomized Control Trial. HOME DES IVUS , 2010 .

[120]  G. Maurer,et al.  Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9. , 2010, JACC. Cardiovascular interventions.

[121]  Y. Hayashi,et al.  Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher Registry). , 2010, The American journal of cardiology.

[122]  M. Leon,et al.  Sex‐specific outcomes following revascularization with zotarolimus‐eluting stents: Comparison of angiographic and late‐term clinical results , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[123]  T. Akasaka,et al.  Serial angiographic findings and prognosis of stent fracture site without early restenosis after sirolimus-eluting stent implantation. , 2010, American heart journal.

[124]  P. Serruys,et al.  Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: Two‐year angiographic and three‐year clinical results from the SPIRIT II study , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[125]  A. Zwinderman,et al.  Genetic variation in PCAF, a key mediator in epigenetics, is associated with reduced vascular morbidity and mortality: evidence for a new concept from three independent prospective studies , 2010, Heart.

[126]  S. Brener,et al.  The relationship between late lumen loss and restenosis among various drug-eluting stents: a systematic review and meta-regression analysis of randomized clinical trials. , 2011, Atherosclerosis.

[127]  S. Fichtlscherer,et al.  A prospective, single-blind, multicenter, dose escalation study of intracoronary iNOS lipoplex (CAR-MP583) gene therapy for the prevention of restenosis in patients with de novo or restenotic coronary artery lesion (REGENT I extension). , 2011, Human gene therapy.

[128]  G. Campo,et al.  Long-term outcomes with cobalt-chromium bare-metal vs. drug-eluting stents: the REgistro regionale AngiopLastiche dell'Emilia-Romagna registry , 2011, Journal of cardiovascular medicine.

[129]  Baseline C-reactive protein serum levels and in-stent restenosis pattern after m-TOR inhibitors drug-eluting stent implantation. , 2011, The Journal of invasive cardiology.

[130]  G. Stone,et al.  Meta-analysis of randomized studies comparing intravascular ultrasound versus angiographic guidance of percutaneous coronary intervention in pre-drug-eluting stent era. , 2011, The American journal of cardiology.

[131]  Paul H. A. Quax,et al.  Restenosis after PCI. Part 2: prevention and therapy , 2012, Nature Reviews Cardiology.

[132]  V. Gudnason,et al.  Hemostatic Factors and Risk of Coronary Heart Disease in General Populations: New Prospective Study and Updated Meta-Analyses , 2013, PloS one.

[133]  H. Kwon,et al.  Prospective Study , 2020, Encyclopedia of Behavioral Medicine.